These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 975731)

  • 41. Torsades de pointes due to n-acetylprocainamide.
    Stevenson WG; Weiss J
    Pacing Clin Electrophysiol; 1985 Jul; 8(4):528-31. PubMed ID: 2410877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
    Moffett BS; Cannon BC; Friedman RA; Kertesz NJ
    Pharmacotherapy; 2006 Dec; 26(12):1687-93. PubMed ID: 17125432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide.
    Ylitalo P; Hinkka H
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):548-53. PubMed ID: 4066079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.
    Simons KJ; Levy RH; Cutler RE; Christopher GT; Lindner A
    Res Commun Chem Pathol Pharmacol; 1975 Jun; 11(2):173-85. PubMed ID: 1153866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets.
    Graffner C; Johnsson G; Sjögren J
    Clin Pharmacol Ther; 1975 Apr; 17(4):414-23. PubMed ID: 1122683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.
    Somogyi A; McLean A; Heinzow B
    Eur J Clin Pharmacol; 1983; 25(3):339-45. PubMed ID: 6194997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Procainamide-cimetidine drug interaction in elderly male patients.
    Bauer LA; Black D; Gensler A
    J Am Geriatr Soc; 1990 Apr; 38(4):467-9. PubMed ID: 2329253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions.
    Atkinson AJ; Lee WK; Quinn ML; Kushner W; Nevin MJ; Strong JM
    Clin Pharmacol Ther; 1977 May; 21(5):575-87. PubMed ID: 322922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration.
    Domoto DT; Brown WW; Bruggensmith P
    Ann Intern Med; 1987 Apr; 106(4):550-2. PubMed ID: 2435200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and
    Jeong YS; Balla A; Chun KH; Chung SJ; Maeng HJ
    Pharmaceutics; 2019 Mar; 11(3):. PubMed ID: 30845766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.
    Bagwell EE; Walle T; Drayer DE; Reidenbert MM; Pruett JK
    J Pharmacol Exp Ther; 1976 Apr; 197(1):38-48. PubMed ID: 1263131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiac anticholinergic effects of procainamide and its N-acetylated metabolite: experimental pharmacological and radioligand binding studies.
    Boucher M; Chassaing C; Laborde P; Breysse C; Herbet A
    J Auton Pharmacol; 1998 Apr; 18(2):83-7. PubMed ID: 9730262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pharmacokinetic comparison of two sustained-release oral procainamide preparations.
    Hore P; Bones P; Rollinson T; Ikram H
    Br J Clin Pharmacol; 1979 Sep; 8(3):267-71. PubMed ID: 497093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-Acetylprocainamide kinetics after single and repeated oral doses.
    Ludden TM; Crawford MH
    Clin Pharmacol Ther; 1982 Mar; 31(3):343-9. PubMed ID: 6174262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.